Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
MacroGenics
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Metastatic castration-resistant adenocarcinoma of the prostate without evidence of neuroendocrine differentiation, signet cell, or small cell features.
Participants must have ≥ 1 metastatic (measurable or non-measurable per PCWG3) lesion.
Participant has prostate cancer progression at study entry based on PCWG3 criteria.
Participant shows evidence of disease progression after receiving at least 1 prior androgen receptor axis-targeted therapy (ARAT) regimen (e.g., abiraterone, enzalutamide, apalutamide, or darolutamide).
Patients with known history of documented breast cancer gene (BRCA) mutation (germline or somatic) must have received an approved poly ADP ribose polymerase (PARP) inhibitor regimen.
Participants must have adequate performance status, life expectancy and laboratory values.
You may not be if
Any condition preventing participant's ability to receive, tolerate, or comply with the planned treatment or study procedures.
Received prior chemotherapy for mCRPC or checkpoint inhibitors for prostate cancer.
Current active or chronic infections.
Any clinically significant heart, lung, or gastrointestinal disorders.
Allergy to any of the study treatments or components of the study treatments.
Clareo Health | A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
